142 related articles for article (PubMed ID: 10588060)
1. AgNORs in breast tumours.
Ceccarelli C; Trerè D; Santini D; Taffurelli M; Chieco P; Derenzini M
Micron; 2000 Apr; 31(2):143-9. PubMed ID: 10588060
[TBL] [Abstract][Full Text] [Related]
2. Improvement of breast cancer prognostication using cell kinetic-based silver-stainable nucleolar organizer region quantification of the MIB-1 positive tumor cell compartment.
Biesterfeld S; Farokhzad F; Klüppel D; Schneider S; Hufnagl P
Virchows Arch; 2001 May; 438(5):478-84. PubMed ID: 11407476
[TBL] [Abstract][Full Text] [Related]
3. Demonstration of silver-stained nucleolar organizer region associated proteins (AgNORs) after wet autoclave pretreatment in breast carcinoma: correlation to tumor stage and long-term survival.
Ofner D; Bier B; Heinrichs S; Berghorn M; Dünser M; Hagemann HA; Langer D; Böcker W; Schmid KW
Breast Cancer Res Treat; 1996; 39(2):165-76. PubMed ID: 8872325
[TBL] [Abstract][Full Text] [Related]
4. Proliferation assessment in breast cancer: a double-staining technique for AgNOR quantification in MIB-1 positive cells especially adapted for image cytometry.
Lorenzato M; Abboud P; Lechki C; Browarnyj F; O'Donohue MF; Ploton D; Adnet JJ
Micron; 2000 Apr; 31(2):151-9. PubMed ID: 10588061
[TBL] [Abstract][Full Text] [Related]
5. Cell cycle-dependent AgNOR analysis in invasive breast cancer.
Krüger S; Stahlhut M; Müller H
Anal Quant Cytol Histol; 2000 Oct; 22(5):358-63. PubMed ID: 11064811
[TBL] [Abstract][Full Text] [Related]
6. Different proliferation patterns in breast cancer: AgNOR measurements in ER-negative and ER-positive tumor cells.
Günther L; Hufnagl P; Winzer KJ; Guski H
Anal Cell Pathol; 2000; 20(4):155-62. PubMed ID: 11205318
[TBL] [Abstract][Full Text] [Related]
7. A clinicopathological evaluation of nucleolar organizer region proteins in human breast carcinoma.
Yoshida Y; Okamura T; Yano K; Kodate M; Oyama T; Inutsuka K; Taga S; Ezaki T
Surg Oncol; 1994 Feb; 3(1):53-7. PubMed ID: 8186871
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of quantitatively measured AgNORs in ductal mammary carcinoma.
Aubele M; Auer G; Jütting U; Falkmer U; Gais P
Anal Quant Cytol Histol; 1994 Jun; 16(3):211-8. PubMed ID: 7522453
[TBL] [Abstract][Full Text] [Related]
9. Argyrophilic nucleolar organizer region (AgNOR) area per nucleus as a prognostic factor in breast cancer.
Nakayama K; Abe R
J Surg Oncol; 1995 Nov; 60(3):160-7. PubMed ID: 7475065
[TBL] [Abstract][Full Text] [Related]
10. Nucleolus organizer regions (AgNORs) in ductal mammary carcinoma. Comparison with classifications and prognosis.
Aubele M; Auer G; Gais P; Jütting U; Rodenacker K; Voss A
Pathol Res Pract; 1994 Feb; 190(2):129-37. PubMed ID: 7520163
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of AgNORs in breast cancer].
Aubele M; Auer G; Jütting U
Zentralbl Pathol; 1994 Mar; 140(1):55-60. PubMed ID: 7515674
[TBL] [Abstract][Full Text] [Related]
12. AgNOR analysis of atypical ductal hyperplasia and intraductal carcinoma of the breast.
Guski H; Hufnagl P; Kaufmann O; Krause M; Winzer KJ
Anal Quant Cytol Histol; 2000 Jun; 22(3):206-12. PubMed ID: 10872036
[TBL] [Abstract][Full Text] [Related]
13. Relationship between AgNOR proteins, Ki-67 antigen, p53 immunophenotype and differentiation markers in archival breast carcinomas.
Bànkfalvi A; Schmitz K; Mock T; Kemper M; Cubick C; Böcker W
Anal Cell Pathol; 1998; 17(4):231-42. PubMed ID: 10391375
[TBL] [Abstract][Full Text] [Related]
14. Quantity of AgNORs in gastric endocrine carcinoid tumours as a potential prognostic tool.
Giuffrè G; Mormandi F; Barresi V; Bordi C; Tuccari G; Barresi G
Eur J Histochem; 2006; 50(1):45-50. PubMed ID: 16584984
[TBL] [Abstract][Full Text] [Related]
15. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters.
Buck A; Schirrmeister H; Kühn T; Shen C; Kalker T; Kotzerke J; Dankerl A; Glatting G; Reske S; Mattfeldt T
Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1317-23. PubMed ID: 12271413
[TBL] [Abstract][Full Text] [Related]
16. Prognostic relevance of AgNORs in tumor pathology.
Pich A; Chiusa L; Margaria E
Micron; 2000 Apr; 31(2):133-41. PubMed ID: 10588059
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of the AgNOR parameter in human breast cancer depends on the pRb and p53 status.
Derenzini M; Ceccarelli C; Santini D; Taffurelli M; Treré D
J Clin Pathol; 2004 Jul; 57(7):755-61. PubMed ID: 15220371
[TBL] [Abstract][Full Text] [Related]
18. AgNOR staining and quantification.
Trerè D
Micron; 2000 Apr; 31(2):127-31. PubMed ID: 10588058
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of standardized AgNOR analysis and Ki-67 immunostaining in gastrointestinal stromal tumors.
Rodolico V; Martorana A; Gulotta G; Diana G; Leonardi V; Cocorullo G; Ajello F
Anal Quant Cytol Histol; 2003 Aug; 25(4):199-209. PubMed ID: 12961826
[TBL] [Abstract][Full Text] [Related]
20. Nucleolar organizer regions in human breast cancer.
Roller E; Fritz P; Wicherek C; Klumpp B; Lauinger J; Mischlinski A; Wanner B; Schumacher K
Zentralbl Pathol; 1993 Aug; 139(3):195-9. PubMed ID: 8218120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
